Investors

Creating long-term value
Creating long-term value

News & Events

Date Event Description
21 Oct 2014

Q3 Results 2014

Webcast with financial results for the first 9 months of 2014

16 Feb 2015

FY Results 2014

Webcast with financial results for the full year of 2014

16 Apr 2015

Q1 Results 2015

Webcast with financial results for the first 3 months of 2015

08 May 2015

AGM

The Annual General Meeting of Shareholders

Learn more about the events

GRIPHON Results webcast

GRIPHON reults webcast

Actelion will present the top-line results of the pivotal Phase III GRIPHON outcome in patients with pulmonary arterial hypertension.

The slide deck is available here.

GRIPHON reults webcast

Actelion will present the top-line results of the pivotal Phase III GRIPHON outcome in patients with pulmonary arterial hypertension.

The slide deck is available here.

Financial Information

CHF million

(except for per share data)

Results

HY 2014

Results

HY 2013

Variance
in CHF %

Variance
at CER %

Product sales

993

884

12

17

Core operating expenses

571

553

3

7

Core earnings

421

331

27

35

Diluted Core EPS

3.25

2.34

39

48

Diluted US GAAP EPS

3.62

1.73

109

124

No of shares in calculation

116.192

115.154

-

-

Share price

ATLN SIX Swiss Exchange

At 17:30:06 CET 19/09/2014
CHF 111,50Up Down image
+1,90 (+1,73%)
 

key information

On 22 July 2014 Actelion announced the Half Year 2014 financial results. These results were accompanied by the publication of the company's Half Year Report.

 
Learn more
 

Contact

Investor Relations
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Phone:+41 61 565 62 62
Fax:+41 61 565 65 07